SOURCE: MicroMed Cardiovascular, Inc.

April 18, 2007 16:36 ET

MicroMed COO & CFO to Be Interviewed on MN1

HOUSTON, TX -- (MARKET WIRE) -- April 18, 2007 --Join both Robert (Bob) J. Benkowski, COO of MicroMed Cardiovascular, Inc. (OTCBB: MMCV), and Juliet Markovich, CFO of MicroMed, on Market News First ( in an exclusive live roundtable interview with the MN1 news team. The interview will take place on Thursday, April 19, 2007 at 10:00 am CDT.

Drs. Michael E. DeBakey, George Noon, NASA and MicroMed jointly developed what is now known as The DeBakey VAD® or ventricular assist device. The DeBakey VAD® is an implantable axial flow device designed to provide long term, improved quality of life for patients who suffer from severe heart failure. It is the only device that provides accurate, real-time flow measurement improving the clinicians' patient care. It is CE-mark approved in Europe for the indications of Pediatric, Bridge-to-transplant & Destination Therapy. In the U.S. it is undergoing an IDE Bridge-to-transplant clinical study in the U.S. and the DeBakey VAD® Child is the only FDA approved implantable pediatric ventricular assist device. MicroMed's manufacturing facility, located in Houston, Texas, is ISO 13485:2003 certified.

For more information, visit

This news release contains certain forward-looking statements pertaining to future anticipated projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this news release that are not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These statements by their nature are estimates of future results only and involve substantial risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors including, but not limited to, risks related to: our ability to obtain additional funding to support our business activities; the early-stage market for ventricular assist products and services; an expected dramatic rise in expenses; rapid growth and change in our business; as well as those risks more fully discussed in the Company's reports filed from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. We do not undertake any obligation to update any forward-looking statements to reflect events or circumstances after the date of this release.

The MicroMed DeBakey VAD® is an investigational device and is limited by federal law for investigational use in the United States.


Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live radio web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

Contact Information

  • Market News First
    Angela Junell